Home / Market News / $ABT
benzinga Corporate Catalyst Impact 65/100 ● positive

Abbott Laboratories Q3 Adj. EPS $1.42, Inline, Sales $13.013B Beat $12.998B Estimate

Oct 21, 2026, 11:31 AM UTC · Primary ticker $ABT

Abbott Laboratories reported Q3 adjusted EPS that met analyst expectations and sales that slightly exceeded estimates. This indicates a stable performance for the company, with year-over-year growth in both earnings and revenue, suggesting continued operational strength.

Abbott Laboratories announced its Q3 earnings, reporting adjusted EPS of $1.42, which was in line with analyst consensus. Sales came in at $13.013 billion, slightly beating the $12.998 billion estimate. This performance represents a 9.23% increase in EPS and a 14.46% increase in sales year-over-year, indicating healthy growth. For traders, this suggests a stable outlook for ABT in the short term, as the company is meeting expectations and demonstrating revenue growth. The slight sales beat could provide a minor positive sentiment, but the inline EPS prevents a significant upward catalyst. The key opportunity lies in the consistent growth, which could attract long-term investors, while the lack of a major surprise limits short-term volatility.

$ABT positive Met EPS, beat sales estimates
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.